Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Illuminating Lujo virus glycoprotein structure, receptor engagement and neutralizing antibody epitopes

Award Number: R21AI180853
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/24/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

Illuminating Lujo virus glycoprotein structure, receptor engagement and neutralizing antibody epitopes - Project Summary The Mammarenavirus genus of the Arenavirus family contains multiple zoonotic pathogens with the potential to cause hemorrhagic fever. These include the South American viruses Junin virus (JUNV; Argentinian hemorrhagic fever) and Machupo virus (MACV; Bolivian hemorrhagic fever), and Lassa virus (LASV), which causes thousands of cases of Lassa Fever in West Africa each year. The case fatality rate for these viruses is 20-70%. Lujo virus (LUJV) is the most recently identified African arenavirus. This virus was responsible for five infections, of which four were fatal. Notably, this outbreak was characterized by human-to-human transmission rather than transmission between rodent and human, as is most common for other arenaviruses. Arenaviruses are genetically and geographically divided into New World (e.g. JUNV and MACV) and Old World (e.g. LASV) groups. Its African location placed LUJV into the OW group. However, LUJV is genetically divergent from other African arenaviruses and is phylogenetically equidistant between the NW and OW groups. Further, its glycoprotein GPC recognizes a different receptor and is antigenically distinct from the other arenaviruses. As the only protein expressed on the viral surface, GPC is responsible for receptor engagement, cell tropism and entry, and is the primary target of antibodies. Understanding the unique structure and surface chemistry of LUJV GPC in its native conformation is key to understanding receptor recognition in the native trimer context, what antibody targets might be on this divergent virus, and how we might design vaccines and therapeutics should the virus re-emerge. The premise of this proposal is that structures of the medically relevant LUJV GP alone and in complex with its cell surface receptor will reveal reasons for its unique cell entry requirements and any differences in its epitope landscape. We will use state-of-the-art biophysical techniques such as cryo electron microscopy, surface plasmon resonance and composition-gradient multiangle light scattering, to characterize the interaction of the prefusion-stabilized LUJV GP trimer (pfGP-TD) with its receptor NRP2. In Aim 2, we will identify antibodies from mice immunized with LUJV pfGP-TD using the Berkeley Lights Beacon platform. Results from the innovative research proposed here will launch multiple lines of inquiry for future studies and will help guide development of vaccines against a diverse range of arenaviruses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	3/4/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $221,888 )
2025	2025	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	10/25/2024	NON-COMPETING CONTINUATION	$221,888
														Subtotal = $221,888

Issue Date FY: 2024 ( Subtotal = $274,500 )
2024	2024	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	11/24/2023	NEW	$247,050
2024	2024	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	001	1	9/11/2024	NEW	$27,450
														Subtotal = $274,500

Grand Total All Awards = $496,388

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Illuminating Lujo virus glycoprotein structure, receptor engagement and neutralizing antibody epitopes

Award Number: R21AI180853

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/24/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer